Early Detection of Colorectal Cancer May Be Possible with Newly Found Biomarkers
the Cancer Therapy Advisor take:
According to a new study published in the British Journal of Cancer, researchers from the Life Science Research Unit at the University of Luxembourg in Walferdange, Luxembourg, have identified two new biomarkers that may contribute to the early detection of colorectal cancer.
For the study, the researchers analyzed tissue samples from patients with various stages of colorectal cancer and from healthy people. The researchers found a large reduction in proteins Suppressor of Cytokine Signaling 2 and 6 (SOCS2 and SOCS6) in both precancerous and cancercous colorectal cells. SOCS proteins are crucial to normal cell growth and their absence may play a role in the uncontrolled growth of cancer cells.
In addition, analyses showed that SOCS2 may act as an early predictor of cancer severity. The findings suggest that both proteins, particularly SOCS2, could be utilized as a biomarker for the early diagnosis of colorectal cancer. The researchers hope to translate their findings into a clinical investigation to determine whether SOCS2 can be used as a biomarker to detect colorectal cancer early.
According to the American Cancer Society, colorectal cancer is the third most common cancer diagnosed in both male and female Americans, and if diagnosed early, 9 in 10 cases can be cured.
Two new biomarkers that may contribute to the early detection of colorectal cancer.
A new study published in the British Journal of Cancer promises to open up new avenues toward swifter diagnosis of colorectal cancer by identifying two potential biomarkers for the early detection of the disease.
Despite progress over recent decades, colorectal cancer remains one of the most deadly cancers worldwide. A cancer biomarker is a molecule whose presence - or absence - in tissue may indicate that tumors are developing. Haan and colleagues examined the detailed analysis of 800 tests of tissue samples from patients at various stages of colorectal cancer and from healthy individuals.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML